Effect of antidepressants for cessation therapy in betel-quid use disorder: a randomised, double-blind, placebo-controlled trial.

Chung-Chieh HungChien-Hung LeeAlbert Min-Shan KoHsien-Yuan LaneChi-Pin LeeYing-Chin Ko

Published in: Epidemiology and psychiatric sciences (2020)

Prescribing a fixed dose of moclobemide and escitalopram to BUD patients over 8 weeks demonstrated treatment benefits to BQ-CC. Given a relatively small sample, this study provides preliminary evidence and requires replication in larger trials.

Keyphrases

double blind
clinical trial
placebo controlled
major depressive disorder
study protocol
end stage renal disease
newly diagnosed
ejection fraction
primary care
open label
randomized controlled trial
emergency department
phase ii
bone marrow
combination therapy
patient reported
adverse drug
cell therapy